1. Home
  2. AGIO vs RVLV Comparison

AGIO vs RVLV Comparison

Compare AGIO & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • RVLV
  • Stock Information
  • Founded
  • AGIO 2007
  • RVLV 2003
  • Country
  • AGIO United States
  • RVLV United States
  • Employees
  • AGIO N/A
  • RVLV N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • RVLV Catalog/Specialty Distribution
  • Sector
  • AGIO Health Care
  • RVLV Consumer Discretionary
  • Exchange
  • AGIO Nasdaq
  • RVLV Nasdaq
  • Market Cap
  • AGIO 1.4B
  • RVLV 1.4B
  • IPO Year
  • AGIO 2013
  • RVLV 2019
  • Fundamental
  • Price
  • AGIO $38.80
  • RVLV $22.52
  • Analyst Decision
  • AGIO Buy
  • RVLV Buy
  • Analyst Count
  • AGIO 6
  • RVLV 14
  • Target Price
  • AGIO $57.40
  • RVLV $26.79
  • AVG Volume (30 Days)
  • AGIO 976.6K
  • RVLV 1.5M
  • Earning Date
  • AGIO 07-31-2025
  • RVLV 08-05-2025
  • Dividend Yield
  • AGIO N/A
  • RVLV N/A
  • EPS Growth
  • AGIO N/A
  • RVLV 38.54
  • EPS
  • AGIO 11.13
  • RVLV 0.63
  • Revenue
  • AGIO $40,875,000.00
  • RVLV $1,182,554,000.00
  • Revenue This Year
  • AGIO $18.94
  • RVLV $7.80
  • Revenue Next Year
  • AGIO $201.70
  • RVLV $7.80
  • P/E Ratio
  • AGIO $3.49
  • RVLV $35.53
  • Revenue Growth
  • AGIO 30.57
  • RVLV 10.68
  • 52 Week Low
  • AGIO $23.42
  • RVLV $16.80
  • 52 Week High
  • AGIO $62.58
  • RVLV $39.58
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 58.69
  • RVLV 61.85
  • Support Level
  • AGIO $34.71
  • RVLV $20.62
  • Resistance Level
  • AGIO $37.73
  • RVLV $21.97
  • Average True Range (ATR)
  • AGIO 1.50
  • RVLV 1.17
  • MACD
  • AGIO 0.15
  • RVLV 0.17
  • Stochastic Oscillator
  • AGIO 82.21
  • RVLV 92.31

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About RVLV Revolve Group Inc.

Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.

Share on Social Networks: